
Angela J Okragly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2893910/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ELEVATED TRYPTASE, NERVE GROWTH FACTOR, NEUROTROPHIN-3 AND GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR LEVELS IN THE URINE OF INTERSTITIAL CYSTITIS AND BLADDER CANCER PATIENTS. Journal of Urology, 1999, 161, 438-442.	0.2	217
2	An Acid-Treatment Method for the Enhanced Detection of GDNF in Biological Samples. Experimental Neurology, 1997, 145, 592-596.	2.0	106
3	Cervical Dorsal Rhizotomy Increases Brain-Derived Neurotrophic Factor and Neurotrophin-3 Expression in the Ventral Spinal Cord. Journal of Neuroscience, 2000, 20, RC77-RC77.	1.7	49
4	LIGHTâ€deficiency impairs CD8+ T cell expansion, but not effector function. International Immunology, 2003, 15, 861-870.	1.8	40
5	IL-33 released by alum is responsible for early cytokine production and has adjuvant properties. Scientific Reports, 2015, 5, 13146.	1.6	37
6	GDNF is abundant in the adult rat gut. Journal of the Autonomic Nervous System, 1998, 70, 115-122.	1.9	35
7	Tumor-derived death receptor 6 modulates dendritic cell development. Cancer Immunology, Immunotherapy, 2008, 57, 777-787.	2.0	21
8	Human mast cells release the migraine-inducing factor pituitary adenylate cyclase-activating polypeptide (PACAP). Cephalalgia, 2018, 38, 1564-1574.	1.8	17
9	Interleukin-33 Contributes Toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production. Frontiers in Immunology, 2018, 9, 2871.	2.2	15
10	Elevated levels of Interleukin (IL)-33 induce bone pathology but absence of IL-33 does not negatively impact normal bone homeostasis. Cytokine, 2016, 79, 66-73.	1.4	10
11	Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33. Journal of Inflammation Research, 2021, Volume 14, 3823-3835.	1.6	6
12	Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis. British Journal of Dermatology, 2022, 187, 599-602.	1.4	6
13	Facile generation and use of immunogenic polypeptide fusions to a sparingly soluble non-antigenic protein carrier. Journal of Immunological Methods, 2000, 236, 53-69.	0.6	5